OCT adds new director ahead of testing its lead compound in Australia, aiming £1.8bn market
February 29, 2024Oxford Cannabinoid Technologies Holdings, the biotech company developing prescription cannabinoid medicines, has appointed Lord Mott OBE as an independent Non-Executive Director, effective immediately.
Lord Mott has held senior positions in a range of organisations, including experience in relation to private equity and venture capital. Lord Mott currently serves on the board of an endowment fund, supporting the contribution of capital and achieving the long-term aims of its investors.
Lord Mott previously served as a Lord in Waiting. In that role he worked with the Foreign, Commonwealth & Development Office, Department for Energy and NetZero, Cabinet Office and Northern Ireland Office. He also served as a founding board member and director of the British Digital Private Markets Association. From March 2020 to November 2022, Lord Mott was Chief Executive Officer of the Conservative and Unionist Party.
Clarissa Sowemimo-Coker, Chief Executive Officer of OCT, expressed delight to welcome Lord Mott as Non-Executive Director at this exciting stage for the Company as it prepares to start its Phase I clinical trial for OCT130401 in Australia, targeting the £1.8bn global Trigeminal Neuralgia market.
Lord Mott expressed pleasure to be joining OCT, pointing out a thrilling time for that step, as it prepares to begin clinical trials for its second programme.
